Amit Z, Brown Z W, Levitan D E, Ogren S O
Arch Int Pharmacodyn Ther. 1977 Nov;230(1):65-75.
Ethanol-drinking rats were injected with the dopamine-beta-hydroxylase inhibitor FLA-57, prior to free-choice presentations of ethanol and water either for 5 alternate days (25 or 40 mg/kg i.p.) or for 5 consecutive days (45 mg/kg i.p.). In all cases, the FLA-57 treated animals markedly attenuated ethanol consumption while vehicle-injected controls showed no change from baseline. In the post-injection period ethanol intake gradually returned to baseline levels. Biochemical assays revealed that whole brain norepinephrine levels following injection of FLA-57 (15-60 mg/kg i.p.) were significantly depressed while dopamine and serotonin levels were slightly increased. It is suggested that norepinephrine may be involved in the mediation of the positive reinforcing properties of ethanol regulating its self-administration.
给饮用乙醇的大鼠注射多巴胺-β-羟化酶抑制剂FLA-57,然后让其自由选择乙醇和水,持续5天交替饮用(腹腔注射25或40毫克/千克)或连续饮用5天(腹腔注射45毫克/千克)。在所有情况下,接受FLA-57治疗的动物乙醇摄入量显著减少,而注射赋形剂的对照组与基线相比无变化。在注射后阶段,乙醇摄入量逐渐恢复到基线水平。生化分析显示,注射FLA-57(腹腔注射15 - 60毫克/千克)后,全脑去甲肾上腺素水平显著降低,而多巴胺和血清素水平略有升高。提示去甲肾上腺素可能参与介导乙醇调节自身给药的正性强化特性。